Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

Inclusion Criteria: * I1. Male or female ≥ 18 years * greater than or equal to 70 years of age with or without any risk factor * or less than 70 years of age and the presence of at least one of the following risk factors: * Arterial hypertension under treatment (all stages) * Obesity (body mass index \[BMI\] ≥30 kg/m²) or severe obesity (BMI of ≥40 kg/m²) * Diabetes (all types) * Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension) * Stroke or cerebrovascular disease History * Chronic lung diseases, including COPD (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension * Malignancies (solid tumors or blood malignancies) that are progressive or were diagnosed less than 5 years ago * Immunocompromised state (this includes patients who are suffering from primary immunodeficiencies; patients under treatment with corticosteroids either oral or parenteral; patients receiving active chemotherapy; patients on biological treatment or treatment with Janus Kinase (JAK) inhibitors) * Solid organ or blood stem cell transplant * Down syndrome * Known human immunodeficiency virus (HIV) infection * Liver disease of stage 1 and 2 based on the Child-Pugh classification (Appendix C) * Hemoglobin blood disorders (Thalassemia, Sickle Cell Disease, etc) * Renal disease (grade 1 and 2 according to Kidney Disease Improving Global Outcomes (KDIGO) classification) (see Appendix D) * Dementia or other neurological conditions * Absence of anti-SARS-CoV2 IgM or IgG at screening * I2. Written informed consent provided by the patient or by a legal representative * I3. Biologically confirmed SARS-CoV-2 infection ≤ 10 days before screening * I4. First onset of COVID-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, fatigue, the new loss of taste or smell * I5. Findings in chest-X-ray or chest computed tomography compatible with lower respiratory tract infection\* \* precision for imaging: typical imaging features related to COVID-19 * I6. Patient admitted to hospital for COVID-19, but outside of the Intensive Care Unit * I7. Patient requiring low-flow O2 supplementation ≤ 6L/min by mask or nasal prongs at screening * I8. The score of 5 on the WHO 11-point Clinical Progression Scale at screening Exclusion Criteria: * E1. Score ≥ 6 on the WHO 11-point Clinical Progression Scale at screening * E2. Respiration rate \> 30 breaths/min in adults under low-flow (⩽ 6 L/min) oxygen * E3. Liver failure of stage 3 according to the Child-Pugh classification * E4. Severe renal failure (≥ grade 3 according to KDIGO classification) * E5. Treatment with anti-SARS-CoV-2 immunoglobulins or any blood-derived products in the last 90 days * E6. Any anti-SARS-CoV-2 vaccine injection performed less than 21 days before screening * E7. Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study * E8. Known allergy or hypersensitivity or intolerance to study product components * E9. History of anaphylaxis during a prior administration of equine serum (i.e., anti- tetanus serum or anti-ophidic serum or anti-arachnid toxin serum or anti-rabies serum) or allergic reaction due to contact or exposure to horses * E10. Participation in any other Interventional study with an investigational product in the last 30 days or within 5 half-lives of receiving the investigational product * E11. Patients with short life expectancy or with any severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study * E12. Septic shock